Bio-Thera(SH:688177) Cai Jing Wang·2025-08-22 05:42Core Viewpoint - Baiyoutai has signed a licensing and commercialization agreement with STADA for BAT1806 (Tocilizumab) injection, granting STADA exclusive commercialization rights in several regions, which is expected to positively impact the company's future performance and enhance its global commercialization and profitability [1][2]. Group 1: Agreement Details - The total amount of upfront and milestone payments can reach up to €136 million, including an upfront payment of €8.5 million and milestone payments not exceeding €127.5 million, along with a double-digit percentage of net sales as revenue sharing [1]. - The agreement covers the commercialization rights in the EU, Switzerland, the UK, parts of other European countries, parts of the Middle East and North Africa (MENA), and some Commonwealth of Independent States (CIS) countries [1]. Group 2: Product Information - BAT1806 (Tocilizumab) is a biosimilar developed by Baiyoutai, targeting the interleukin-6 receptor (IL-6R) and is approved by the NMPA in China, the FDA in the US, and the EMA in Europe [2]. - The product is marketed under the name Shiruili in China and TOFIDENCE in the US [2]. Group 3: STADA Overview - STADA is a well-established European pharmaceutical company headquartered in Germany, focusing on three strategic pillars: consumer health, generics, and specialty pharmaceuticals [2]. - In the fiscal year 2024, STADA achieved a group sales revenue of €4.059 billion, with an adjusted EBITDA of €886 million, and employs approximately 11,649 people globally [2].